Replies to post #317343 on Amarin Corp Plc (AMRN)

[Whalatane]

Hi BC. good to see you posting again .

For those that don't know BC .....he's traded in and out of AMRN successfully over the years ....Yes , he actually has been able to sell the stock some times , most notably earlier this year when he posted he was selling AMRN to buy TSLA .......as it turned out a great move.. altho some trashed him for it at the time .

BC. re your purchases at $3.80 to $4.30 ....I was buying around the same time as posted as such

Whalatane Tuesday, 11/24/20 11:07:33 PM
Re: postes post# 311628 0
Post # of 317389
Nope...most recent purchase was 11/13 at $4.1 ....before that it was on 11/6 at $4.6
Average cost is roughly $4.35
If it drops below $4 you can write a post on Kiwi's " massive losses " :--)
Kiwi

I'm giving AMRN until the EMA approval ...which I expect in April ( as per HDG's time line if I recall correctly )...anyway until then to make some fundamental headway in the US .
We need to see that JT can grow scripts faster than the generics can supply the market .......if not... he needs to slash marketing spend ( if scripts are still going sideways ) or make a deal with the generics pr make a deal with Apotex and supply them as a competing authorized generic .

The wildcard is Covid. Kaiser with all their resources in Ca could do at least a quick retrospective study ...poster Iryo and I have discussed this previously ...on wether or not Vascepa is reducing severity of events in their CAD patients on Vascepa , that are coming down with Covid.

The market in the EU is fragmented and besides Germany will take time to develop. Countries like Poland may not provide any coverage at all ...and Poland is around 40m people .
China is a royalty play and most of the ROW will not find Vascepa as currently priced ...to be affordable
JMO
Good luck ...by the way glad TSLA worked out for you. KOD was one of my best performers this year ...Baker Bros now own about 28% of the Co
Kiwi